The Access Houston Airports is optimized with tools for children with developmental disabilities to use during their travels in and out of Houston. Photo courtesy of the Houston Airport System

Houston's two airports have a new digital tool to help its passengers with developmental disabilities better navigate their journey in and out of town.

George Bush Intercontinental Airport and William P. Hobby Airport have partnered with Chicago-based Autism innovation company, Infiniteach, to launch the Access Houston Airports mobile app. The free technology provides tools to children with autism or other conditions — as well as their caregivers — throughout their Houston Airport System experience.

"Houston Airports continues to embrace technology to go the extra mile to assist passengers of all abilities on their journey through our airports," says Jesus Saenz, Houston Airports' COO, in a news release.

The Centers for Disease Control and Prevention estimates that 13 percent of the United states have an "invisible" developmental disability like autism. Tim Joniec, the director of government relations and Americans with Disability Act coordination at HAS, says in the release that this translates to 20,000 daily Houston travelers.

"Houston Airports is introducing this app to ease anxiety for these families and provide information and resources that will make their visit to the airport an engaging and meaningful experience," Joniec says in the release.

The app uses researched-based strategies and features, including guides, short picture stories, scheduling tool, checklist feature, as well as caregiver information like terminal maps and support.

The app launch is just one improvement HAS has made. The organization has also conducted employee disability awareness training, Aira technology for the blind or low vision, service dog familiarization training, and nonprofit involvement through Southwest Airlines and United Airlines' annual Wings for all event.

Users can set a schedule for themselves, which can give them some comfort as they travel and accomplish tasks. Courtesy of HAS

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.